Cambridge Cognition Holdings plc strong sales performance

Commenting on the results Steven Powell, Chief Executive Officer of Cambridge Cognition, said: “The first half has been characterised by the Company delivering against its promised strategy as evidenced by a strong sales performance. Our continued investment in R&D means that we remain at the forefront of innovation in digital health and neuroscience and have created platforms for further, future commercial growth.”

The neuroscience technology company Cambridge Cognition Holdings plc (LON: COG), which develops and markets digital solutions to assess brain health, announced its unaudited Interim Results for the six months ended 30 June 2018.

Strong sales performance and order pipeline entering second half

An encouraging first half performance with 13% like for like sales growth provides evidence that the investment made in the commercial operation is beginning to reap rewards.

Financial & Operational Highlights

· Like for like revenue +13% to £3.63m (H1 2017: £3.21m)

· Major contract win delivered in March 2018

· Ratio of Orders received to Revenue of 1.77

· Like for like loss before tax of £0.22m (H1 2017: £0.39m loss)

· Sales orders more than doubled to £4.87m (H1 2017: £2.13m)

– NeuroVocalix voice platform generating revenue with pharmaceutical partners

– Wearable technology increased +356% to £0.70m

– CANTAB Recruit increased by +335% to £0.39m

Financial results under new accounting standard IFRS 15 (see note 3 to interim financial statement)

· Reported revenue of £2.75m

· Reported loss before tax of £1.02m

· Loss per share of 5.0p

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions